Russell D. Japikse, MD, PhD; James E. Svenson, MD, MS; Perry J. Pickhardt, MD; Michael D. Repplinger, MD, PhD
WMJ. 2019;118(1):173-176
ABSTRACT
Introduction: Segmental arterial mediolysis (SAM) is a rare nonatherosclerotic, noninflammatory vasculopathy causing arterial wall necrosis that leads to strictures, dissections, and aneurysms, particularly in medium-sized abdominal arteries. Awareness of SAM is important because, unlike vasculitides, immunosuppressive treatment may worsen the disease process.
Case: A 58-year-old man with multiple medical comorbidities presented with acute epigastric pain and a right incarcerated inguinal hernia that was interpreted as showing bowel strangulation on computed tomography. The hernia was unable to be educed in the emergency department, so the patient was taken for open reduction by the surgical service. Intraoperatively, he was noted to have a ruptured superior mesenteric artery aneurysm. Conventional angiography demonstrated a bead-like appearance of several jejunal branches of the superior mesenteric artery, raising concern for a vasculitis. His hospital course included rheumatologic consultation, and initial recommendations were to start immunosuppressive therapy for treatment of polyarteritis nodosa. Further testing demonstrated normal antinuclear antibody, antineutrophil cytoplasmic antibodies, and complement levels. Due to a lack of systemic symptoms or signs and otherwise unremarkable laboratory evaluation, the patient ultimately was diagnosed with SAM and immunosuppressive therapy was halted.
Discussion: Unexplained medium arterial stenosis, dissection, aneurysm, and hemorrhage should raise suspicion for possible SAM. The initial management approach should focus on treatment of the acute hemorrhage, usually involving endovascular stenting or coil embolization. Unlike vasculitides, SAM does not benefit from, and may actually be harmed by, immunosuppressive therapy.
Conclusions: Clinicians involved in the longitudinal care of emergency department patients should be aware of this rare clinical entity in order to initiate appropriate treatment.